i bet on losing dogs lyrics
NoneWayne Rooney sends I’m A Celeb star wife Coleen a sweet video message as he begs fans to vote her Queen of the JungleCAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows: Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial Abstract Number: SESS-2211 Session: Concurrent Poster Spotlight Session 7: Targeting the ER and PI3K pathway: Novel drugs and combinations Date/Time: Wednesday, December 11, 8:00-9:30 a.m. ET (7:00-8:30 a.m. CT) Conference Call Information Relay Therapeutics will host a conference call to discuss these data on Wednesday, December 11, 2024 at 7:00 a.m. ET (6:00 a.m. CT). Registration and dial-in for the conference call and webcast may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations . An archived replay of the webcast will be available following the event. The poster will be available at the start of the session on the company’s website at https://relaytx.com/publications/ . About RLY-2608 RLY-2608 is the lead program in Relay Therapeutics’ efforts to discover and develop mutant selective inhibitors of PI3Kα, the most frequently mutated kinase in all cancers, with oncogenic mutations detected in about 14% of patients with solid tumors. RLY-2608 has the potential, if approved, to address more than 300,000 patients per year in the United States, one of the largest patient populations for a precision oncology medicine. Traditionally, the development of PI3Kα inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3Kα and off-isoform activity. Toxicity related to inhibition of WT PI3Kα and other PI3K isoforms results in sub-optimal inhibition of mutant PI3Kα with reductions in dose intensity and frequent discontinuation. The Dynamo® platform enabled the discovery of RLY-2608, the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3Kα, performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3Kα, and leveraged these insights to support the design of RLY-2608. RLY-2608 is currently being evaluated in a first-in-human trial designed to treat patients with advanced solid tumors with a PIK3CA (PI3Kα) mutation. For more information on RLY-2608, please visit here . About Relay Therapeutics Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics’ strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics’ portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, including lirafugratinib as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection and the expectations regarding Relay Therapeutics’ use of capital, expenses and potential cost savings. The words “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics’ drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics’ ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Relay Therapeutics’ most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact: Megan Goulart 617-322-0814 mgoulart@relaytx.com Media: Dan Budwick 1AB 973-271-6085 dan@1abmedia.com
AP News Summary at 1:51 p.m. ESTQuick response saves Saskatchewan hockey player’s life after neck slashed - 650 CKOM News Talk Sports
NoneTop 10 Best Anti-Money Laundering (AML) Companies in India 2025 | Leading AML SolutionsSwift's daily impact on Vancouver may have exceeded 2010 Games, says industry figure
READER POLL: How would you grade the Orioles’ signing of Tyler O’Neill?
Waverton Investment Management Ltd cut its holdings in NVIDIA Co. ( NASDAQ:NVDA – Free Report ) by 3.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,459 shares of the computer hardware maker’s stock after selling 830 shares during the quarter. Waverton Investment Management Ltd’s holdings in NVIDIA were worth $2,729,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Other hedge funds also recently bought and sold shares of the company. Legal & General Group Plc boosted its position in shares of NVIDIA by 884.0% in the 2nd quarter. Legal & General Group Plc now owns 213,127,959 shares of the computer hardware maker’s stock worth $26,329,751,000 after purchasing an additional 191,469,114 shares in the last quarter. Bank of New York Mellon Corp grew its position in NVIDIA by 854.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 182,622,629 shares of the computer hardware maker’s stock valued at $22,561,200,000 after purchasing an additional 163,482,580 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of NVIDIA by 870.3% in the second quarter. Ameriprise Financial Inc. now owns 102,422,225 shares of the computer hardware maker’s stock worth $12,658,922,000 after buying an additional 91,867,031 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in NVIDIA by 1,123.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 92,039,713 shares of the computer hardware maker’s stock valued at $11,371,255,000 after purchasing an additional 84,515,429 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of NVIDIA by 808.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 82,689,605 shares of the computer hardware maker’s stock worth $10,215,474,000 after purchasing an additional 73,589,208 shares during the last quarter. Hedge funds and other institutional investors own 65.27% of the company’s stock. NVIDIA Stock Performance Shares of NVDA stock opened at $137.01 on Friday. The company’s 50 day moving average is $139.97 and its 200 day moving average is $127.90. The company has a quick ratio of 3.64, a current ratio of 4.10 and a debt-to-equity ratio of 0.13. The firm has a market cap of $3.36 trillion, a price-to-earnings ratio of 53.92, a PEG ratio of 2.43 and a beta of 1.64. NVIDIA Co. has a 52-week low of $47.32 and a 52-week high of $152.89. NVIDIA Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Friday, December 27th. Shareholders of record on Thursday, December 5th were paid a $0.01 dividend. The ex-dividend date of this dividend was Thursday, December 5th. This represents a $0.04 annualized dividend and a yield of 0.03%. NVIDIA’s dividend payout ratio (DPR) is 1.57%. Analyst Ratings Changes NVDA has been the topic of a number of recent analyst reports. Needham & Company LLC raised their price target on shares of NVIDIA from $145.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, November 21st. Stifel Nicolaus boosted their price target on NVIDIA from $165.00 to $180.00 and gave the company a “buy” rating in a research note on Tuesday, November 19th. Raymond James increased their price objective on shares of NVIDIA from $140.00 to $170.00 and gave the stock a “strong-buy” rating in a research note on Thursday, November 14th. Benchmark increased their price target on shares of NVIDIA from $170.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, November 21st. Finally, Evercore ISI boosted their price target on NVIDIA from $189.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Four investment analysts have rated the stock with a hold rating, thirty-nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $164.15. Check Out Our Latest Stock Report on NVIDIA Insiders Place Their Bets In other NVIDIA news, Director Mark A. Stevens sold 125,000 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $122.61, for a total transaction of $15,326,250.00. Following the transaction, the director now owns 8,255,117 shares in the company, valued at approximately $1,012,159,895.37. This represents a 1.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website . Also, Director Tench Coxe sold 1,000,000 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $131.26, for a total transaction of $131,260,000.00. Following the completion of the transaction, the director now directly owns 28,671,360 shares of the company’s stock, valued at approximately $3,763,402,713.60. This represents a 3.37 % decrease in their position. The disclosure for this sale can be found here . Over the last three months, insiders have sold 1,351,886 shares of company stock valued at $176,825,650. 4.23% of the stock is currently owned by insiders. About NVIDIA ( Free Report ) NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. Further Reading Five stocks we like better than NVIDIA How to Capture the Benefits of Dividend Increases S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains Bank Stocks – Best Bank Stocks to Invest In How AI Implementation Could Help MongoDB Roar Back in 2025 What Does a Stock Split Mean? Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon? Receive News & Ratings for NVIDIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NVIDIA and related companies with MarketBeat.com's FREE daily email newsletter .Sterling Holdco Moves Ahead in Recapitalisation
None
Missing 15-year-old inmate may have escaped juvenile detention center in Tampa
When "Squid Game" was released on Netflix in 2021, it took the world by storm. Created by Hwang Dong-hyuk, the acclaimed Korean survival drama spurred plenty of social media chatter, viral challenges and even Halloween costumes on its way to becoming the streamer's most-watched show ever. On Thursday, the Emmy-winning series returns for round two. Season 2 will once again follow Seong Gi-hun (Lee Jung-jae) as he makes his way back to the deadly contest after surviving and winning the big cash prize the last time he played. But this time, his goal isn't to climb out of debt: Gi-hun wants to take out the mastermind and end the games forever. The first time around, the series was hailed as a brutal critique of economic exploitation and capitalist society thanks to its depiction of the contestants' backstories, as well as its focus on how the economically downtrodden are treated by others regardless of the reason for their circumstances. The deadly games are only possible because the future is bleak for so many. Advertisement To prepare for "Squid Game" Season 2 after a three-year hiatus, here is a quick refresher on the key players and events from Season 1. The mysterious Front Man (Lee Byung-hun), center, oversees the deadly contest in "Squid Game." (No Ju-han / Netflix) What is 'Squid Game'? "Squid Game" is a Korean-language series about a secret game that involves a group of debt-ridden contestants assembled to compete in a series of deadly children's games for the chance to win a large cash prize. Contestants who lose or break the rules are killed until only one winner remains. Advertisement Why is it called 'Squid Game'? The... Tracy BrownTrump's threat to impose tariffs could raise prices for consumers, colliding with promise for relief DETROIT (AP) — If Donald Trump makes good on his threat to slap 25% tariffs on everything imported from Mexico and Canada, the price increases that could follow will collide with his campaign promise to give American families a break from inflation. Economists and industry officials say companies would have little choice but to pass along the added costs, dramatically raising prices for food, clothing, automobiles, booze and other goods. The president-elect floated the tariff idea and an additional 10% tax on goods from China, as a way to force the countries to halt the flow of illegal immigrants and drugs into the U.S. But his posts Monday threatening tariffs on his first day in office could be a negotiating ploy to get the countries to change behavior. Trump’s latest tariff plan aims at multiple countries. What does it mean for the US? WASHINGTON (AP) — President-elect Donald Trump has identified what he sees as an all-purpose fix for what ails America: Slap huge new tariffs on foreign goods entering the United States. On Monday, Trump sent shockwaves across the nation’s northern and southern borders, vowing sweeping new tariffs on Mexico, Canada, as well as China, as part of his effort to crack down on illegal immigration and drugs. Trump said he will impose a 25% tax on all products entering the country from Canada and Mexico, and an additional 10% tariff on goods from China, as one of his first executive orders. Canadian officials blast Trump's tariff threat and one calls Mexico comparison an insult TORONTO (AP) — Canadian officials are blasting President-elect Donald’s Trump’s threat to impose sweeping tariffs. The leader of Canada's most populous province on Tuesday called Trump’s comparison of Canada to Mexico “the most insulting thing I’ve ever heard.” Trump has threatened to impose tariffs on products from Canada, Mexico and China as soon as he takes office in January as part of efforts to crack down on illegal immigration and drugs. He said he would impose a 25% tax on all products entering the U.S. from Canada and Mexico. Canadians say their economy and the U.S. one are deeply intertwined and Americans would feel tariffs, too. Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese Americans WASHINGTON (AP) — Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid under a new rule the Biden administration proposed Tuesday morning. The proposal, which would not be finalized until after President-elect Donald Trump takes office, could cost taxpayers as much as $35 billion over the next decade. It would give millions of people access to weekly injectables that have helped people shed pounds so quickly that some people have labeled them miracle drugs. Surveillance tech advances by Biden could aid in Trump's promised crackdown on immigration President-elect Donald Trump will return to power next year with a raft of technological tools at his disposal that would help deliver his campaign promise of cracking down on immigration — among them, surveillance and artificial intelligence technology that the Biden administration already uses to help make crucial decisions in tracking, detaining and ultimately deporting immigrants lacking permanent legal status. One algorithm, for example, ranks immigrants with a “Hurricane Score,” ranging from 1-5, to assess whether someone will “abscond” from the agency’s supervision. Thanksgiving travel is cranking up. Will the weather cooperate? The Thanksgiving travel rush is picking up, with Tuesday and Wednesday expected to be much busier than the last couple days. A lot of travelers will be watching weather forecasts to see if rain or snow could slow them down. The Transportation Security Administration expects to screen more than 2.8 million people on Tuesday and 2.9 million on Wednesday after handling more than 2.5 million people on Monday. So far, relatively few flights have been canceled this week, but there have been thousands of delayed flights every day. That is becoming normal for U.S. airlines. Federal agency raises the size of most single-family loans the government can guarantee to $806,500 The Federal Housing Finance Agency is increasing the size of home loans that the government can guarantee against default as it takes into account rising housing prices. Beginning next year, mortgage buyers Fannie Mae and Freddie Mac will be able to acquire loans of up to $806,500 on single-family homes in most of the country, the agency said Tuesday. The new conforming loan limit is a 5.2% increase from its 2024 level. FHFA oversees Fannie Mae and Freddie Mac, which buy home loans from banks and other lenders. FHFA adjusts the loan limits annually to reflect changes in U.S. home values, which have been rising this year despite a national home sales slump. Stock market today: Wall Street hangs near its records despite tariff talk NEW YORK (AP) — U.S. stocks are hanging near their records on Tuesday as Wall Street takes Donald Trump’s latest talk about tariffs in stride. The S&P 500 rose 0.4% in Tuesday afternoon trading and was on track to top its all-time high set a couple weeks ago. The Dow Jones Industrial Average lost 49 points from its own record set the day before, while the Nasdaq composite rose 0.6%. Stock markets abroad were down, but mostly only modestly, after President-elect Trump said he plans to impose sweeping new tariffs on Mexico, Canada and China as soon as he takes office. Treasury yields rose modestly in the bond market. What Black Friday's history tells us about holiday shopping in 2024 NEW YORK (AP) — The holiday shopping season is about to reach full speed with Black Friday, which kicks off the post-Thanksgiving retail rush later this week. The annual sales event no longer creates the midnight mall crowds or doorbuster mayhem of recent decades, in large part due to the ease of online shopping and habits forged during the COVID-19 pandemic. Hoping to entice equivocating consumers, retailers already have spent weeks bombarding customers with ads and early offers. Still, whether visiting stores or clicking on countless emails promising huge savings, tens of millions of U.S. shoppers are expected to spend money on Black Friday itself this year. Biden administration to loan $6.6B to EV maker Rivian to build Georgia factory that automaker paused ATLANTA (AP) — President Joe Biden’s administration will loan $6.6 billion to electric vehicle maker Rivian Automotive to build a Georgia factory. The announcement Tuesday comes less than two months before Donald Trump becomes president again. It’s unclear whether the Biden administration can complete the loan in that time, or whether the Trump administration might try to claw the money back. Rivian announced a $5 billion Georgia factory in 2021. But the startup automaker couldn't meet production targets and rapidly burned through cash. The company paused construction of the Georgia plant in March. The company now says its plans for producing electric vehicles in Georgia are back on.